Clinical Trial Results: PROPEL can reduce orthodontic treatment 60 percent or more

PROPEL Orthodontics, the developer of innovative orthodontic devices and techniques which dramatically accelerates the rate at which teeth are moved in orthodontic treatment, recently announced it has a concluded a six-month, open label registry clinical trial.

The PROPEL System is a simple three step in-office procedure that can be performed in minutes by any Orthodontist. The PROPEL System uses a university research backed, patented process called Alveocentesis to stimulate alveolar bone in patients undergoing orthodontic treatment. Alveocentesis works by causing a significant increase in cytokine activity, in turn leading to faster bone remodeling. When used in conjunction with any orthodontic treatment modality — including but not limited to Invisalign, SureSmile, and brackets and wires — teeth move 60 percent or more faster.

The results from participating orthodontists treating over 100 patients with PROPEL throughout the U.S. have been exceptional and consistent with the results seen in hundreds of other patients treated in the past two years. Predicted treatment times were reduced by 60 percent or more in a range of cases including spacing, crowding, open bite, cross bite and more. Notable cases included Invisalign treatments in which patients changed clear aligner trays every 10 days versus the standard 14 with no refinements, a pre-prosthetic space creation for a congenitally missing tooth completed in six months, and an adult celebrity patient who was treated with lingual braces in less than one year.

PROPEL Orthodontics has exceeded its pre-orders for the PROPEL System and has begun making the product commercially available to a select group of orthodontists. Production capabilities have been ramped up to meet the overwhelming demand and processes put in place to ensure the strictest quality assurance.

Bryce Way, president and CEO of PROPEL Orthodontics, is pleased to have received exceptional results from the highly anticipated clinical trial; stating, “We are greatly encouraged by the outcome and look forward to continued rapid growth in the orthodontic market. A new benchmark has been set for accelerated orthodontic treatment and we are excited to be the leader.”